Second primary cancers and hormonal therapies for prostate cancer: A nested case–control study
Open Access
- 17 March 2025
- journal article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 39 (2) , e70004
Abstract
Introduction: (Pre‐)clinical studies have not ruled out a potential risk of second primary cancer (SCP) under the effect of some new androgen receptor pathway inhibitors (ARPIs), especially enzalutamide (ENZ).Methods: Using the French health reimbursement claims database (Système National des Données de Santé), we designed a case–control study nested in a 2013–2020 cohort of new users of androgen‐deprivation therapy. The cases were patients with a first diagnosis of SPC, identified beyond 12 months following cohort entry and up to December 31st, 2021; up to 10 controls were matched per case, based on age and cohort entry date. The main analysis focused on patients who had not switched to a different ARPI. Applying a one‐year lag time, we determined the most frequent and longest cumulative exposure patterns to abiraterone (ABI) or ENZ and estimated the odds ratios.Results: The cohort comprised 147 092 patients, including 7928 cases and 78 554 controls eligible for analysis. The SPCs mainly involve the digestive organs, the urinary tract, or the lungs. Recent and short exposure to ENZ was associated with SPC: OR 1.7, 95% CI [1.2–2.4]. Recent one full year of exposure to ABI, as well as full‐year plus part of the second year, was associated with SPC: OR 1.8 [1.2–2.7] and 2.3 [1.3–4.0], respectively.Discussion/Conclusion: SPC cases were mainly observed among recently exposed patients, which could be linked to a detection bias. The insufficient number of patients exposed over many years means that no definitive conclusions can be drawn.Keywords
Funding Information
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
This publication has 41 references indexed in Scilit:
- Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment techniqueRadiotherapy and Oncology, 2014
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tractBJU International, 2009
- Flexible modeling of the cumulative effects of time‐dependent exposures on the hazardStatistics in Medicine, 2009
- Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuriesJournal of Clinical Epidemiology, 2006
- Analysis of Exposure‐Time‐Response Relationships Using a Spline Weight FunctionBiometrics, 2000
- Rodent Leydig Cell Tumorigenesis: A Review of the Physiology, Pathology, Mechanisms, and Relevance to HumansCritical Reviews in Toxicology, 1999
- Leydig cell hyperplasia and adenoma formation: Mechanisms and relevance to humansReproductive Toxicology, 1997
- Neoplastic Lesions of Questionable Significance to HumansToxicologic Pathology, 1994
- INDUCTION AND LATENT PERIODSAmerican Journal of Epidemiology, 1981